Everolimus and Sunitinib potentially work as therapeutic drugs for infantile hemangiomas
Developed a novel immortalized hemangioma-derived endothelial cell (iHemEC) model that replicates key IH features, overcoming limitations of primary cell models. Identified Sunitinib and Everolimus as promising therapeutic candidates with superior efficacy, supported by transcriptome and protein analyses. Revealed distinct drug mechanisms, with Everolimus targeting PI3K/AKT/mTOR and Sunitinib inducing chromosome instability and DNA damage.
Authors
- Rosalind Kieran (ORCID: https://orcid.org/0000-0002-1789-9855)
- Jianfeng Ge (ORCID: https://orcid.org/0000-0003-0972-3312)
- Rongfang Xie (ORCID: https://orcid.org/0000-0001-8922-2766)
- Luying Wang (ORCID: https://orcid.org/0000-0002-0429-1496)
- Zhiyu Li (ORCID: https://orcid.org/0000-0003-0546-3023)
- Miaomiao Li (ORCID: https://orcid.org/0000-0003-4508-196X)
- Xusheng Wang (ORCID: https://orcid.org/0000-0002-0997-8705)
- Changxian Dong (ORCID: https://orcid.org/0000-0003-1812-5015)
- Zhujue Taohuang
Institutions
- Shandong University (CN)
- Sun Yat-sen University (CN)
- University of Cambridge (GB)
- Cancer Research UK (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Zhengzhou University (CN)
- Cancer Research UK Cambridge Center (GB)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Shandong Provincial Hospital (CN)
Publication Details
- Journal
- Pediatric Research
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1038/s41390-025-04028-7
- Citations
- 1
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University